#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Wolfram syndrome Conjunctivitis allergic Congenital absence of bile ducts Progressive supranuclear palsy Endometrial cancer recurrent Rhabdomyosarcoma Chronic myeloid leukaemia Systemic mastocytosis Epidermolysis bullosa Neurodermatitis Follicle centre lymphoma follicular grade I II – III refractory Ventricular fibrillation B precursor type acute leukaemia Neuroblastoma Mantle cell lymphoma stage II More trials…

    Learn about Rare Diseases

    Hairy cell leukaemia – Basic Information Gastrointestinal stromal tumour – Treatment Tuberous sclerosis complex Glycogen storage disease type I Niemann-Pick disease – Diagnostics Gastrointestinal stromal tumour – Basic Information Mucopolysaccharidosis I – Basic Information Familial amyotrophic lateral sclerosis – Treatment Gastrointestinal stromal tumour Lymphangioma More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Retifanlimab Metoclopramide Bms-986458 Larotrectinib Sulfate Hydroxychloroquine Sulfate Lenalidomide Ecoo4 Ep262 Cagrilintide Propofol Prx005 Itolizumab Insulin Aspart Annamycin SAT-3247 OXALATE Glenzocimab NALOXEGOL Eculizumab Rupatadine Nanatinostat More therapies…

    Learn about Your Condition

    Delayed graft function Immune-mediated myositis MELAS syndrome Bronchiectasis Lyme disease Hypotransferrinaemia Pulmonary fibrosis Inflammation Peritoneal neoplasm Acute hepatic failure Malignant peritoneal neoplasm Corticobasal degeneration Thyroid cancer Pulmonary tuberculosis Demyelination More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Male Urogenital Diseases

  • Study on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • 18F-Psma-1007
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Cyprus The Netherlands

  • Study of Lutetium (177Lu) Vipivotide Tetraxetan and Ipilimumab for Men with Very High-Risk Prostate Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Ipilimumab
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Germany

  • Study of RMC-035 to prevent kidney injury in patients undergoing open-chest heart surgery

    Not recruiting

    2 1
    Investigated Diseases:
    • Renal failure
    Investigated Drugs:
    • Rmc-035
    Czechia Germany Spain

  • Study on Dapagliflozin and Balcinrenone for Patients Over 50 with Stage 3 Chronic Kidney Disease

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Balcinrenone
    • Dapagliflozin
    France Germany

  • Study of Pembrolizumab with Radiotherapy for Patients with Recurrent Prostate Cancer After Surgery

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Prostate cancer recurrent
    Investigated Drugs:
    • Pembrolizumab
    Germany

  • Study on the Effectiveness of Relatlimab, Ipilimumab, and Nivolumab in Patients with High-Risk Clear Cell Renal Cell Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Relatlimab
    • Ipilimumab
    • Nivolumab
    The Netherlands
Previous Page
1 … 17 18 19 20 21 … 24
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!